AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
HC Wainwright Reiterates Neutral Recommendation on Co-Diagnostics with 482.52% Upside Potential.
ByAinvest
Monday, Nov 24, 2025 11:23 pm ET1min read
HC Wainwright & Co. reiterated its coverage of Co-Diagnostics with a Neutral recommendation. Analysts forecast an average one-year price target of $2.04/share, a 482.52% increase from its latest closing price of $0.35/share. The projected annual revenue for Co-Diagnostics is $2MM, a 201.25% increase, and the projected annual non-GAAP EPS is 0.38.
Aime Insights
Which companies have consistent earnings growth and high profit margins?
What dividend aristocrats would you suggest for stable income?
How do profit margins compare among leading social media companies over the past five years?
How is the S&P 500 performing today, and could you explain the reasons behind it?
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet